The WHO (World Health Organization) has said that one of the six people must have a hearing loss disorder, but the number of people who realize the problem is no more than 10%, and less than 1% of the hearing aids are actually used. Many people with hearing impairment gradually withdraw from the society. Improving the hearing of this group of people is clearly a potential market for medical companies.

In China, college students and people with common eyes have a myopia rate of more than 80%. The annual number of refractive surgery cases is 700,000 to 800,000. According to experts in the field of ophthalmology, with the application of smart phones, the chances of adults suffering from eye diseases are getting higher and higher, which is obviously a big cake for medical companies. Another example is the continuous emergence of diseases in the respiratory field, which has also enabled Omron to continue to expand in the Chinese market.

In China, the world's second largest medical market, in addition to multinational medical giants, some specialized small giants in the field of disease are already in the depth. In the entire medical market in China, the competition among the small giants in the fine-grained layout of a single field is becoming a trend that is constantly advancing and evolving.

Refined layout

Regarding the difference between big giants and small giants, companies such as Novartis, GSK, and GE, which are widely involved in a wide range of disciplines, are often referred to as big players. In addition, market competitiveness and annual income are also the main measures.

In the past, in the field of treatment, diseases that usually do not threaten human life, such as hearing loss, obstacles, vision loss, myopia, etc., are arranged on the verge of treating diseases. However, with the continuous improvement of people's living standards and health awareness, although it does not pose a threat to life, the diseases that affect the quality of life are gradually being taken seriously.

And with this change, the brightest prospects for the birth are medical companies. For example, in the area of ​​hearing, the Sonova Group is known as the Hearing Kingdom because the group has cochlear implants in addition to hearing aids.

This is a Swiss company specializing in hearing treatment. It is understood that Sonova's new hearing aid is currently implanted in Chinese. In order to achieve this innovation, they have established a branch in Shanghai.

For the development of this field, Lin Zhenhui, president of the Asia-Pacific region of the group, said that he hopes that every hearing-impaired person with hearing loss can enjoy the life of a normal person.

It is understood that 7.4% of the business revenue of this company is used for R&D investment, so the quality of products in the Chinese market is favored by the industry. This is obviously a fundamentally-born company that produces products in China and then exports them to other countries.

Compared with the hearing market layout, ophthalmology is also a specialized market that has emerged in recent years. Zeiss has also quickly formed a layout in the mid-to-high-end, low-end market.

According to relevant information, Zeiss is a leader in the field of optics. He began working on precision machinery and optics workshops 170 years ago. One of the founders, Mr. Abbe, himself is a physicist. He discovered the relevant formulas and imaging principles for calculating lenses, and turned optics into a discipline. He is also one of the founders of modern optical theory. The structure of the eye itself is equivalent to a camera, and Zeiss' technology is widely used in ophthalmology. Ophthalmology is a number of diagnostic and therapeutic devices . Zeiss is the inventor and the manufacturer of the highest technology.

In addition, health companies in the field of pancreatic diseases include Omron. Omron is the world's largest manufacturer of sphygmomanometers. Since entering China in 1993, Omron has experienced rapid development in China for more than 20 years. In 1993, Omron's first factory in China was completed and put into operation in the Dalian Free Trade Zone. Today, this plant has become Omron's largest electronic sphygmomanometer production base in the world, with more than 30 production lines capable of producing 1 million sphygmomanometers per month. In order to better develop the Chinese market, Omron has successively built Dalian No. 2 Factory and Health Medical Product R&D Center. At present, Dalian's two major factories and R&D centers have become Omron's global production bases and R&D bases.

The above companies are generally referred to as “small giants” by their focus on segmentation of diseases, and their market competitiveness in this field has an absolute advantage.

According to a person from Shenwei Pharmaceutical, in the early years, various medical companies diversified their development in order to share risks, including investment and product development and sales. With the increasing complexity of the disease and the fierce competition among pharmaceutical companies, major pharmaceutical companies have focused on their own areas of strength, and since the beginning of last year, the giants have turned to the subdivision. At the moment, the depth of the Chinese giants in the Chinese medical market is becoming an absolute advantage and trend.

market capacity

According to Wang Shufeng, a hearing research expert, according to a group of data analysis by the World Health Organization, there are 360 ​​million hearing-impaired people in the world, accounting for 5.3% of the entire population.

"We have compiled this data according to other different data. The number of elderly people in our country is more than 220 million, 30% of which have ears, including talking and snoring. This is estimated to be more than 6,000 to 7,000. Wan.” Wang Shufeng said that the number of children with hearing impairment is also higher.

According to data from the National Disability Sampling Survey in 1987 and 2006, children aged 0 to 14 have a permanent hearing loss of about 500,000, while among young and middle-aged, there are an estimated 11.5 million because of Chinese youth. Nearly 900 million people, about 10% by 1%.

Therefore, by age, the total number is about 70 million, and the number of patients with more than 70 million is exactly the same as the 5.3% of the total population of 1.36 billion announced by the World Health Organization.

Urine Analyzer

1)High-luminance and white LED, features in long life and good stability.
2)Large LCD screen, high luminance, abundant contents display, optional languages: Chinese and English.
3)User-friendly interface.
4)Optional units: international unit, conventional unit and symbol system.
5)Three working mode: one-step/slow/fast testing mode, suitable for different user group.
6)Monitoring the whole test process, auto-character and audible prompt.
7)Be compatible with 8, 10 and 11-parameter test strip.
8)Standard RS232 interface and interface for data communication.
9)Built-in thermal printer.

Urine Analyzer,Urine Analyser,At Home Water Test,Water Indicator Paper

Changchun LYZ Technology Co., Ltd , https://www.lyzstrips.com